Dear NAMI CC Supporter, Family Member and Friend,
NAMI CC (NAMI Contra Costa) has received a $5,000 grant and is committed to reducing stigma so that those who live with Tardive Dyskinesia can move more freely, with others having a broader understanding of the medical condition. We will not be silent as we share education about how you can support those with TD. We will incorporate information about TD not just through the month of May but included in all of our education programs.
About TD Awareness Week The first full week of #MentalHealthAwarenessMonth is #TDAwarenessWeek. Tardive dyskinesia (TD) is an involuntary movement disorder associated with the use of antipsychotics. Early recognition and treatment can make a positive impact. Learn more: TalkAboutTD.com #Screen4TD
May 4-10, 2025, marks the 8th annual TD Awareness Week, a week dedicated to elevating discussion on TD to reduce stigma and empower the at least 800,000 adults in the U.S. impacted by the condition. May is also Mental Health Awareness Month, and as we work to increase awareness and support for those impacted by mental health conditions, it’s important to remember that those living with a mental health condition who have taken necessary antipsychotic medication may develop or may already have TD.
Tardive dyskinesia (TD) is an involuntary movement disorder that is characterized by uncontrollable movements of the face, torso, limbs and fingers or toes. The condition is associated with use of antipsychotic medication that may be necessary to treat individuals living with mental illnesses such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder. TD is estimated to affect at least 800,000 adults in the United States. Of those living with TD, approximately 60% remain undiagnosed.
Neurocrine Biosciences, Inc. is dedicated to providing education and eliminating stigma associated with TD during TD Awareness Week (May 4–10, 2025) and throughout the year. As part of this awareness week, we are committed to increasing routine screenings to improve earlier recognition and diagnosis of TD. While Neurocrine Biosciences focuses on ongoing efforts to educate about TD, we recognize the first full week in May as another opportunity to inspire others to eliminate stigma associated with TD and elevate the importance of routine screening for TD to improve earlier diagnosis. Follow and join the conversation online by sharing #TDAwarenessWeek and #Screen4TD. Thank you for your participation in efforts to raise awareness of Mental Health Awareness Month and TD Awareness Week.
Mental health continues to be a significant challenge in the U.S., and it is important to include TD in the conversation because of the physical, social and emotional impacts this disorder can have on people trying to maintain mental health stability with antipsychotic medication. Earlier recognition and treatment of TD can make a positive impact for many
people living with a mental illness, including in the lives of their loved ones and care partners.
More information about TD is available at Neurocrine.com/TD-awareness, and resources can be accessed at TalkAboutTD.com.
